Replies to post #70179 on Biotech Values

[DewDiligence]

>"Xalatan an also ran?"
That seems a little harsh, given that it had sales of $1.3 billion or so for the first 9 months…<

Let’s keep this in context: $1.5-2B in annual sales is not that much for a company the size of PFE.

Moreover, Xalatan was the second-largest drug in Pharmacia’s portfolio (behind Celebrex) when PFE paid almost $60B in stock (one-third of PFE’s pre-deal equity) to acquire Pharmacia. Given the economic expectations implicit in these buyout numbers, I think it’s fair to characterize Xalatan as a disappointment.